RIM
LRMR icon

RS Investment Management’s Larimar Therapeutics LRMR Stock Holding History

RS Investment Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-49,676
Closed -$19M – 360
2015
Q3 		$19M Buy
49,676
+11,377
+30% +$5.13M 0.17% 183
2015
Q2 		$15.9M Buy
38,299
+11,958
+45% +$5M 0.14% 212
2015
Q1 		$12.5M Buy
+26,341
New +$12.5M 0.11% 223

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

RS Investment Management's LRMR Position: Q4 2015 in Review

RS Investment Management sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 49,676 shares — an estimated $19M sold.

RS Investment Management first reported a position in LRMR in Q1 2015 and held it in 3 quarters. The position peaked at $19M in Q3 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • RS Investment Management reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • RS Investment Management sold 49,676 Larimar Therapeutics shares in Q4 2015, an estimated $19M.
  • RS Investment Management first reported a position in Larimar Therapeutics in Q1 2015 and held it in 3 quarters.
  • RS Investment Management's Larimar Therapeutics position peaked at $19M in Q3 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on RS Investment Management's 13F filing for Q4 2015, filed 11 Feb 2016.